Lowest Price Guaranteed From USD 4,799
Published
August 2022
Pages
321
View Count
9285
Example Insights
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Report Description
The spatial genomics and spatial transcriptomics market is estimated to be worth $4.7 billion in 2022 and is expected to grow at compounded annual growth rate (CAGR) of 11.9% during the forecast period. Since the discovery of the first human genetic map in 1987, the field of omics-based analysis has evolved significantly. Researchers have focused their efforts from decoding the primary sequence of genes to analyzing the location and interaction of cell types, and biomarkers (primarily, DNA, RNA and proteins), through a process known as spatial phenotyping. The traditional molecular profiling analytical techniques, such as microarrays quantitative polymerase chain reaction (qPCR), flow cytometry, mass spectrometry, immunohistochemistry and enzyme linked immunosorbent (ELISA) assay, though widely adopted, are known to dissociate the tissue samples, thereby causing loss of critical spatial multi-omics information across the genome, transcriptome, and proteome. This unmet need in the life sciences research market has prompted innovators to amalgamate cell imaging and molecular profiling techniques to enable visualization, as well as high-throughput quantification of the cells and biomarkers within the tissue samples. These solutions (that include platforms, along with affiliated reagents and software applications) enable the researchers to further advance and scale their research, by offering a better understanding of the disease morphology, discover novel biomarkers and develop precision therapies. Additionally, these spatial phenotyping platforms can be seamlessly integrated with the current NGS-workflows. Therefore, the adoption of these novel devices to scale research from discovery to translational and clinical phases, is on the rise. In fact, according to a recent survey, approximately 44% of respondents expressed their intent to purchase a spatial profiling platform. In the same year, a research study, published in JAMA Oncology, emphasized the superiority of spatial phenotyping methods for the biomarker analysis in patients suffering from immuno-oncological diseases. Further, Nature Methods dubbed Spatial Transcriptomics as “Method of the Year” for 2020.
In order to capitalize the growing opportunity within this niche market, the developers of spatial-omics solutions are engaged in efforts to improve the penetration of their proprietary technologies, within the diverse client base, including academic research centers, research institutes and biopharma companies. As a result, they are engaged in incorporating advanced features to their devices, including machine learning-based image analysis, automated sample processing, high-multiplexing, and biomarker-specific gene panels (including those associated with SARS-CoV-2). At the same time, the cost of running these complex tests has dramatically decreased in recent years; the spatial analysis of high-plex stained panels now costs USD 1,000 per slide, which is similar to the cost of whole genome sequencing by NGS. Further, these instruments are designed to be capable of processing formalin-fixed paraffin embedded (FFPE) tissue sample. This feature is important because nearly 80% of the translational research studies, that use tissue samples, are dependent on the aforementioned sample type. Few players have also introduced customized access programs for biopharmaceutical players, enabling them to leverage spatial omics technologies, for the purpose of guiding their drug development programs. Driven by the growing adoption and continuous innovation of spatial biology solutions, we are led to believe that the opportunity for spatial profiling solution providers is likely to witness a sustained growth over the coming years.
Several recent developments have taken place in the field of spatial genomics. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The “Spatial Genomics, Transcriptomics and Proteomics Solutions Market by Type of Solution (Instruments, Consumables and Services), Type of Sample (DNA, RNA and Proteins), End Users (Pharmaceutical and Biotechnology Companies, and Academic and Research institutes), Research Areas (Oncology, Immunology, Neurology, Infectious and Others), and Key Geographical Regions (North America, Europe, and Asia-Pacific and the Rest of the World): Industry Trends and Forecasts, 2022-2035” report offers an extensive study on the current market landscape, offering an informed opinion on the likely evolution of the spatial omics solutions market. The study underlines an in-depth analysis, highlighting the diverse capabilities of various industry stakeholders engaged in this domain. Amongst other elements, the report includes:
One of the key objectives of the report was to estimate the existing market size and the potential future growth opportunity associated with spatial omics solutions providers in the mid to long term. We have developed informed estimates on the evolution of the market for the period 2022-2035. Our year-wise projections of the current and forecasted opportunity have further been segmented across different segments; type of solution (instruments, services, consumables and software), type of sample analyzed (DNA, RNA and proteins), end user (academic research institutes and pharmaceutical companies), research areas (oncology, immunology, neurology, infectious and others), and key geographical locations (North America, Europe and Asia- Pacific and the Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, which represent different tracks of the industry’s growth.
The opinions and insights presented in the report were influenced by discussions held with several stakeholders engaged in this domain. The report features detailed transcripts of discussions held with the following individuals:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
Chapter 2 is an executive summary of the key insights captured during our research. It offers a high-level view on the current state and likely evolution of the spatial omics solutions market, in the mid to long term.
Chapter 3 provides a general introduction to spatial omics solutions, the need and evolution of these solutions. In addition, the chapter includes information on the various features of spatial analysis solutions and the techniques used in spatial biology analysis, particularly focusing on fluorescence microscopy, brightfield microscopy, and mass spectroscopy. The chapter also discusses the different components and working procedure of spatial analysis instruments, and the potential of spatial profiling solutions across oncological and non-oncological disease areas. Further, the chapter provides an overview of the existing challenges and future anticipated trends, within this domain.
Chapter 4 provides an overview of the current market landscape of the spatial genomics, transcriptomics and proteomics solutions, including information on 40+ players offering these solutions, along with information on their year of establishment, company size (large, mid–sized and small), ownership (private, public), geographical location of headquarters (North America, Europe and Asia-Pacific), commercial availability (commercialized and under developed), type of solution(s) offered (product and / or service), type of sample(s) analyzed (fresh frozen, FFPE, tissue microarrays and cellular), compatible sample source (human, murine), supported labware for sampling (test tubes, slides and well plates), type of molecule(s) analyzed (RNA, DNA and protein), detection method(s) used (fluorescence, brightfield and mass spectrometry), maximum plex level, quantification capability of analyte, research area(s) and application area(s).
Chapter 5 provides an insightful competitiveness analysis of spatial omics technologies, based on parameters, such as supplier strength (in terms of years of experience of developer and company size), and portfolio diversity (type of sample analyzed, supported labware for sampling, type of molecule analyzed, detection method used, maximum plex level, quantification capability and compatible sample source).
Chapter 6 includes detailed profiles of prominent solution providers in this domain. Each company profile includes a brief overview of the company, its financial information (if available), information on its spatial biology solutions portfolio, recent developments, and an informed outlook.
Chapter 7 presents an analysis of the partnerships and collaborations established for spatial genomics, transcriptomics and proteomics solutions during 2017-2022, featuring a detailed set of analyses based on various parameters, such as the type of partnership, year of partnership, therapeutic areas involved, geographical location of the companies involved and the most active players.
Chapter 8 presents in-depth analysis of the patents that have been filed / granted for spatial profiling solutions since 2003. It highlights trends across the key parameters associated with the patents, including type of patent, patent application year, publication year, number of granted patents and patent applications, geography, patent age, type of applicant, CPC symbols, leading industry and non-industry players (on the basis of number of patents), and individual patent assignees (in terms of size of intellectual property portfolio). The chapter also includes an insightful benchmarking and valuation analysis.
Chapter 9 presents a detailed review 600+ peer-reviewed, scientific articles related to research on spatial omics solutions, based on parameters, such as year of publication, type of publication and popular keywords. The chapter also provides information on the top journals, top publishers, and top copyright holders (in terms of number of articles published).
Chapter 10 presents a detailed review of the overall landscape of the live cell instruments market, highlighting the contributions of industry players, along with information on their year of establishment, company size (large, mid-sized and small), geographical location of headquarters(North America, Europe, Asia-Pacific), ownership (private, public), commercial availability (commercialized, under developed), microscope configuration (inverted, upright), instrument weight, availability of integrated incubator, environmental parameters controlled (temperature, humidity, gas control, pH and osmolarity), availability of multi-user mode, supported labware (flasks, dishes, slides, plates, well plates, microfluidic chips and hemocytometers), Z-stack imaging capability, autofocusing capability, mode of imaging (fluorescence, brightfield, phase- contrast, confocal, differential interference contrast (DIC), Hoffman modulation contrast (HMC) and colorimetric, number of fluorescent channels and magnification.
Chapter 11 provides an overview of genome sequencing technologies landscape, featuring information on the type of applications, run time, maximum reads per run, maximum sequencing output, maximum read length, type of sequencing technique, quality score and cost. It also provides information on the technology providers involved in this domain, including information on their year of establishment, company size and geographical location.
Chapter 12 presents an insightful market forecast analysis, highlighting the future potential of the spatial genomics, transcriptomics, and proteomics solutions market, till 2035. In order to provide a detailed future outlook, our projections have been segmented across different segments on the basis of [A] type of solution (instruments, consumables and services), [B] type of sample (DNA, RNA and protein), [C] end users (pharmaceutical and biotechnology companies, and academic and research institutes), [D] research areas (oncology, immunology, neurology, infectious and others), [E] key geographical locations (North America, Europe and Asia-Pacific and the Rest of the World).
Chapter 13 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with Priyam Shah, (Senior Director, Akoya Biosciences), Sean Bendall (Co-founder, Ionpath) and Brad Nelson (Senior Vice President of Marketing, Ionpath)
Chapter 14 is a summary of the overall report, presenting the insights on the contemporary market trends and the likely evolution of the spatial analysis market.
Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.
Chapter 16 is an appendix, which provides a list of companies and organizations mentioned in this report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
2.1. Chapter Overview
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Spatial Biology
3.3. Overview of Spatial Omics Solutions
3.3.1. Historical Overview of Spatial Omics Solutions
3.3.2. Features of Spatial Omics Solutions
3.3.3. Workflow of Spatial Omics Instruments
3.3.4. Computational Methods for Spatial Omics
3.3.5. Application Area(s)
3.4. Concluding Remarks
4. SPATIAL OMICS SOLUTIONS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. List of Spatial Omics Solutions
4.2.1. Analysis by Commercial Availability
4.2.2. Analysis by Type of Solution(s)
4.2.3. Analysis by Type of Sample(s) Analyzed
4.2.4. Analysis by Supporting Labware
4.2.5. Analysis by Type of Molecule(s) Analyzed
4.2.6. Analysis by Detection Method(s) Used
4.2.7. Analysis by Maximum Plex Level
4.2.8. Analysis by Quantification Capability
4.2.9. Analysis by Research Area(s)
4.2.10. Analysis by Application Area(s)
4.2.11. Analysis by Compatible Sample Source(s)
4.2.12 Analysis by Compatible Sample Source(s) and Type of Sample(s) Analyzed
4.2.13 Analysis by Quantification Capability and Type of Molecule(s) Analyzed
4.2.14 Analysis by Detection Method(s) Used and Maximum Plex Level
4.3. Spatial Omics Solution Providers: List of Players
4.3.1. Analysis by Type of Player
4.3.2. Analysis by Year of Establishment
4.3.3. Analysis by Player Size
4.3.4. Analysis by Location of Headquarters
4.3.5. Analysis by Company Ownership
4.3.6. Analysis by Year of Establishment and Location of Headquarters
4.3.7. Analysis by Player Size and Location of Headquarters
4.3.8. Analysis by Leading Players
4.4. Spatial Omics Solutions: List of Kits
4.5. Spatial Omics Solutions: Funding and Investments
5. SPATIAL OMICS SOLUTIONS: PRODUCT COMPETITIVENESS ANALYSIS
5.1 Chapter Overview
5.2 Assumptions / Key Parameters
5.3 Methodology
5.4 Product Competitiveness Analysis: Spatial Omics Solutions
5.4.1 Peer Group I: Small Companies
5.4.2. Peer Group II: Mid-sized Companies
5.4.3. Peer Group III: Large Companies
6. SPATIAL OMICS SOLUTIONS: COMPANY PROFILES
6.1. Chapter Overview
6.2. Spatial Omics Analysis Solution Providers: North America
6.2.1. 10x Genomics
6.2.1.1. Company Overview
6.2.1.2. Financial Information
6.2.1.3. Product Portfolio
6.2.1.4. Recent Developments and Future Outlook
6.2.2. Akoya Biosciences
6.2.2.1. Company Overview
6.2.2.2. Financial Information
6.2.2.3. Product Portfolio
6.2.2.4. Recent Developments and Future Outlook
6.2.3. Bruker
6.2.3.1. Company Overview
6.2.3.2. Financial Information
6.2.3.3. Product Portfolio
6.2.3.4. Recent Developments and Future Outlook
6.2.4. Canopy Biosciences
6.2.4.1. Company Overview
6.2.4.2. Product Portfolio
6.2.4.3. Recent Developments and Future Outlook
6.2.5. NanoString Technologies
6.2.5.1. Company Overview
6.2.5.2 Financial Information
6.2.5.3. Product Portfolio
6.2.5.4. Recent Developments and Future Outlook
6.2.6. Vizgen
6.2.6.1. Company Overview
6.2.6.2. Product Portfolio
6.2.6.3. Recent Developments and Future Outlook
6.3. Spatial Omics Analysis Solution Providers: Europe
6.3.1. Lunaphore Technologies
6.3.1.1. Company Overview
6.3.1.2. Product Portfolio
6.3.1.3. Recent Developments and Future Outlook
6.3.2. Molecular Machines & Industries (MMI)
6.3.2.1. Company Overview
6.3.2.2. Product Portfolio
6.3.2.3. Recent Developments and Future Outlook
6.3.3. Resolve Biosciences
6.3.3.1. Company Overview
6.3.3.2. Product Portfolio
6.3.3.3. Recent Developments and Future Outlook
7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Spatial Omics Solutions: List of Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Type of Partner
7.3.4. Analysis by Year of Partnership and Type of Partner
7.3.5. Analysis by Type of Partnership and Type of Partner
7.3.6. Analysis by Therapeutic Area
7.3.7. Intercontinental and Intracontinental Agreements
7.3.8. Analysis by Regional Distribution
7.3.9. Most Active Players: Analysis by Number of Partnerships
8. PATENT ANALYSIS
8.1. Chapter Overview
8.2 Scope and Methodology
8.3 Spatial Omics Solutions: Patent Analysis
8.3.1. Analysis by Application Year
8.3.2. Analysis by Publication Year
8.3.3. Analysis by Geography
8.3.4. Analysis by CPC Symbols
8.3.5. Word Cloud: Emerging Focus Areas
8.3.6. Analysis by Type of Applicant
8.3.7. Leading Players: Analysis by Number of Patents
8.3.8. Leading Patent Assignees: Analysis by Number of Patents
8.4. Spatial Omics Solutions: Patent Benchmarking Analysis
8.5. Spatial Omics Solutions: Patent Valuation
8.6. Leading Patents: Analysis by Number of Citations
9. PUBLICATION ANALYSIS
9.1. Chapter Overview
9.2 Scope and Methodology
9.3. Spatial Omics Solutions: List of Publications
9.3.1. Analysis by Year of Publication (2001-2022)
9.3.2. Analysis by Year and Quarterly Trend of Publication (2015-2021)
9.3.3. Analysis by Month and Quarterly Trend of Publication (2015-2021)
9.3.4. Analysis by Type of Publication
9.3.5. Most Popular Journals: Analysis by Number of Publications
9.3.6. Most Popular Journals: Analysis by Journal Impact Factor
9.3.7. Most Popular Publishers: Analysis by Number of Publications
9.3.8. Most Popular Copyright Holder: Analysis by Number of Publications
9.3.9. Analysis by Popular Keywords
9.3.10. Most Popular Authors: Analysis by Number of Publications
9.3.11. Analysis by Affiliated Institutes
9.3.12. Analysis by Most Targeted Research Area
9.3.13. Analysis by Geography
10. CASE STUDY ON POTENTIAL CLIENTS OF SPATIAL OMICS SOLUTION PROVIDERS
10.1. Chapter Overview
10.2. Live Cell Imaging Instruments Providers: Overall Market Landscape
10.2.1. Analysis by Year of Establishment
10.2.2. Analysis by Company Size
10.2.3. Analysis by Location of Headquarters
10.2.4. Analysis by Company Type
10.2.5. Analysis by Year of Establishment and Location of Headquarters
10.2.6. Analysis by Company Size and Location of Headquarters
10.2.7. Year-Wise Distribution of Commercial Availability
10.2.8. Analysis by Microscope Weight
10.2.9. Analysis by Microscope Configuration
10.2.10. Analysis by Incubator Integrated and Environmental Parameters Controlled
10.2.11. Analysis by Supported Labware
10.2.12. Analysis by Mode of Imaging
10.2.13. Analysis by Multi-user Mode
10.2.14. Analysis by Z-stack Imaging Capability
10.2.15. Analysis by Availability of Autofocusing / Semi-Autofocusing Ability
10.2.16. Analysis by Mode of Imaging, Multi-user mode, Z-Stack Imaging and Autofocusing Semi-autofocusing Capability
10.2.17. Analysis by Number of Fluorescence Channels
10.2.18. Analysis by Magnification
11. CASE STUDY ON SEQUENCING TECHNOLOGIES
11.1. Chapter Overview
11.2. Genome Sequencing Technologies: Overall Market Landscape
11.2.1. Analysis by Type of Sequencing Technique
11.2.2. Analysis by Maximum Output
11.2.3. Analysis by Maximum Reads per Run
11.2.4. Analysis by Method of Sequencing
11.3 Genome Sequencing Technology Providers: Overall Market Landscape
11.3.1. Analysis by Year of Establishment
11.3.2. Analysis by Company Size
11.3.3. Analysis by Location of Headquarters
12. SPATIAL OMICS SOLUTION PROVIDERS: MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1 Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Global Spatial Omics Solutions Market, 2022-2035
12.3.1 Spatial Omics Solutions Market: Distribution by Type of Solution, 2022-2035
12.3.1.1 Spatial Omics Solutions Market for Instruments, 2022-2035
12.3.1.2 Spatial Omics Solutions Market for Services, 2022-2035
12.3.1.3 Spatial Omics Solutions Market for Consumables and Software, 2022-2035
12.3.2. Spatial Omics Solutions Market: Distribution by Type of Sample, 2022-2035
12.3.2.1 Spatial Omics Solutions Market for Proteins, 2022-2035
12.3.2.2 Spatial Omics Solutions Market for RNA, 2022-2035
12.3.2.3 Spatial Omics Solutions Market for DNA, 2022-2035
12.3.3. Spatial Omics Solutions Market: Distribution by Research Area, 2022-2035
12.3.3.1 Spatial Omics Solutions Market for Oncological and Immuno-Oncological Disorders, 2022-2035
12.3.3.2 Spatial Omics Solutions Market for Immunological Disorders, 2022-2035
12.3.3.3 Spatial Omics Solutions Market for Neurological Disorders, 2022-2035
12.3.3.4 Spatial Omics Solutions Market for Infectious Diseases, 2022-2035
12.3.3.5 Spatial Omics Solutions Market for Other Research Areas, 2022-2035
12.3.4. Spatial Omics Solutions Market: Distribution by End User, 2022-2035
12.3.4.1 Spatial Omics Solutions Market for Pharmaceutical and Biotechnology Companies, 2022-2035
12.3.4.2 Spatial Omics Solutions Market for Academic and Research Institutes, 2022-2035
12.3.5. Spatial Omics Solutions Market: Distribution by Key Geographical Regions, 2022-2035
12.3.5.1 Spatial Omics Solutions Market in North America, 2022-2035
12.3.5.2 Spatial Omics Solutions Market in Europe, 2022-2035
12.3.5.3 Spatial Omics Solutions Market in Asia-Pacific and Rest of the World, 2022-2035
12.4. Spatial Omics Solutions Market for Instruments, 2022-2035
12.4.1. Spatial Omics Solutions Market for Instruments: Distribution by Type of Sample, 2022-2035
12.4.2. Spatial Omics Solutions Market for Instruments: Distribution by Research Area, 2022-2035
12.4.3. Spatial Omics Solutions Market for Instruments: Distribution by End User, 2022-2035
12.4.4. Spatial Omics Solutions Market for Instruments: Distribution by Key Geographical Regions, 2022-2035
12.5. Spatial Omics Solutions Market for Services, 2022-2035
12.5.1. Spatial Omics Solutions Market for Services: Distribution by Type of Sample, 2022-2035
12.5.2. Spatial Omics Solutions Market for Services: Distribution by Research Area, 2022-2035
12.5.3. Spatial Omics Solutions Market for Services: Distribution by End User, 2022-2035
12.5.4. Spatial Omics Solutions Market for Services: Distribution by Key Geographical Regions, 2022-2035
12.6. Spatial Omics Solutions Market for Consumables and Software, 2022-2035
12.6.1. Spatial Omics Solutions Market for Consumables and Software: Distribution by Type of Sample, 2022-2035
12.6.2. Spatial Omics Solutions Market for Consumables and Software: Distribution by Research Area, 2022-2035
12.6.3. Spatial Omics Solutions Market for Consumables and Software: Distribution by End User, 2022-2035
12.6.4. Spatial Omics Solutions Market for Consumables and Software: Distribution by Key Geographical Regions, 2022-2035
13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. Akoya Biosciences
13.2.1. Chapter Snapshot
13.2.2. Interview Transcript
13.3. Ionpath
13.3.1. Chapter Snapshot
13.3.2. Interview Transcript
14. CONCLUDING REMARKS
14.1. Chapter Overview
15. APPENDIX 1: TABULATED DATA
16. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Segments of Spatial Biology
Figure 3.2 Analytical Techniques employed in Spatial Omics Solutions
Figure 3.3 Historical Timeline of the Launch of Spatial Omics Solutions
Figure 3.4 Important Features of Spatial Analysis Solutions
Figure 3.5 Workflow of Spatial Omics Instruments
Figure 3.6 Preparation of Tissue Samples for Spatial Omics Analysis
Figure 3.7 Steps Involved in Spatial Data Downstream Analysis
Figure 4.1 Spatial Omics Solutions: Distribution by Commercial Availability
Figure 4.2 Spatial Omics Solutions: Distribution by Type of Solution(s) Offered
Figure 4.3 Spatial Omics Solutions: Distribution by Type of Sample(s) Analyzed
Figure 4.4 Spatial Omics Solutions: Distribution by Supporting Labware
Figure 4.5 Spatial Omics Solutions: Distribution by Type of Molecule(s) Analyzed
Figure 4.6 Spatial Omics Solutions: Distribution by Detection Method(s) Used
Figure 4.7 Spatial Omics Solutions: Distribution by Maximum Plex Level
Figure 4.8 Spatial Omics Solutions: Distribution by Quantification Capability
Figure 4.9 Spatial Omics Solutions: Distribution by Research Area(s)
Figure 4.10 Spatial Omics Solutions: Distribution by Application Area(s)
Figure 4.11 Spatial Omics Solutions: Distribution by Compatible Sample Source(s)
Figure 4.12 Spatial Omics Solutions: Distribution by Compatible Sample Source(s) and Type of Sample(s) Analyzed
Figure 4.13 Spatial Omics Solutions: Distribution by Quantification Capability and Type of Molecule(s) Analyzed
Figure 4.14 Spatial Omics Solutions: Distribution by Detection Method(s) Used and Maximum Plex Level
Figure 4.15 Spatial Omics Solution Providers: Distribution by Type of Players
Figure 4.16 Spatial Omics Solution Providers: Distribution by Year of Establishment
Figure 4.17 Spatial Omics Solution Providers: Distribution by Company Size
Figure 4.18 Spatial Omics Solution Providers: Distribution by Location of Headquarters
Figure 4.19 World Map Representation: Distribution by Geography
Figure 4.20 Spatial Omics Solution Providers: Distribution by Company Ownership
Figure 4.21 Spatial Omics Solution Providers: Distribution by Year of Establishment and Location of Headquarters
Figure 4.22 Spatial Omics Solution Providers: Distribution by Player Size and Location of Headquarters
Figure 4.23 Leading Industry Players: Distribution by Number of Solutions Offered
Figure 5.1 Product Competitiveness Analysis: Distribution of Spatial Omics Solutions Offered by Small Companies (Peer Group 1)
Figure 5.2 Product Competitiveness Analysis: Distribution of Spatial Omics Solutions Offered by Mid-sized Companies (Peer Group 2)
Figure 5.3 Product Competitiveness Analysis: Distribution of Spatial Omics Solutions Offered by Large Companies (Peer Group
Figure 6.1 10x Genomics: Annual Revenues, FY 2017 - Q2 FY 2022 (USD Billion)
Figure 6.2 Akoya Biosciences: Annual Revenues, FY 2019 - Q2 FY 2022 (USD Million)
Figure 6.3 Bruker: Annual Revenues, FY 2017-Q2 FY 2022 (USD Million)
Figure 6.4 NanoString Technologies: Annual Revenues, FY 2017 - Q2 FY 2022 (USD Billion)
Figure 7.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 7.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 7.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 7.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 7.5 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 7.6 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 7.7 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 7.8 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 7.9 Partnerships and Collaborations: Regional Distribution
Figure 7.10 Most Active Players: Distribution by Number of Partnerships
Figure 8.1 Patent Analysis: Distribution by Type of Patent
Figure 8.2 Patent Analysis: Cumulative Distribution by Application Year, 2003-2021
Figure 8.3 Patent Analysis: Cumulative Distribution by Publication Year, 2003-2022 (till February)
Figure 8.4 Patent Analysis: Distribution by Patent Type and Publication Year, Pre-2015-2022 (till February)
Figure 8.5 Patent Analysis: Distribution by Location of Patent Jurisdiction (Region-wise)
Figure 8.6 Patent Analysis: Distribution by Location of Patent Jurisdiction (Country-wise)
Figure 8.7 Patent Analysis: Distribution by CPC Symbols
Figure 8.8 Patent Analysis: Emerging Focus Areas
Figure 8.9 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant, 2003- 2022 (till February)
Figure 8.10 Leading Industry Players: Distribution by Number of Patents
Figure 8.11 Leading Non-Industry Players: Distribution by Number of Patents
Figure 8.12 Leading Patent Assignees: Distribution by Number of Patents
Figure 8.13 Patent Benchmarking: Distribution of Leading Industry Player by Patent Characteristics (CPC Symbols)
Figure 8.14 Patent Analysis: Distribution by Age
Figure 8.15 Spatial Omics Solutions: Patent Valuation
Figure 9.1 Publication Analysis: Cumulative Year-wise Trend, 2001-2022 (till March)
Figure 9.2 Publication Analysis: Year and Quarterly Trend of Publications,2015-2021
Figure 9.3 Publication Analysis: Quarterly Distribution of Publications, 2015-2022 (till March)
Figure 9.4 Publication Analysis: Distribution by Type of Publication
Figure 9.5 Most Popular Journals: Distribution by Number of Publications
Figure 9.6 Most Popular Journals: Analysis by Journal Impact Factor
Figure 9.7 Most Popular Publishers: Distribution by Number of Publications
Figure 9.8 Most Popular Copyright Holders: Distribution by Number of Publications
Figure 9.9 Publication Analysis: Word Cloud of Study Titles
Figure 9.10 Most Popular Authors: Distribution by Number of Publications
Figure 9.11 Publication Analysis: Distribution by Affiliated Institutes
Figure 9.12 Publication Analysis: Distribution by Most Targeted Research Area
Figure 9.13 Publication Analysis: Distribution by Geography
Figure 10.1 Live Cell Imaging Instruments Providers: Distribution by Year of Establishment
Figure 10.2 Live Cell Imaging Instruments Providers: Distribution by Company Size
Figure 10.3 Live Cell Imaging Instruments Providers: Distribution by Location of Headquarters
Figure 10.4 World Map Representation: Distribution by Geography
Figure 10.5 Live Cell Imaging Instrument Providers: Distribution by Company Type
Figure 10.6 Live Cell Imaging Instrument Providers: Distribution by Year of Establishment and Location of Headquarters
Figure 10.7 Live Cell Imaging Instrument Providers: Distribution by Company Size and Location of Headquarters
Figure 10.8 Live Cell Imaging Instruments: Cumulative Distribution of Commercial Availability
Figure 10.9 Live Cell Imaging Instruments: Distribution by Microscope Weight
Figure 10.10 Live Cell Imaging Instruments: Distribution by Microscope Configuration
Figure 10.11 Live Cell Imaging Instruments: Distribution by Incubator Integrated and Environmental Parameters Controlled
Figure 10.12 Live Cell Imaging Instruments: Distribution by Supported Labware
Figure 10.13 Live Cell Imaging Instruments: Distribution by Mode of Imaging
Figure 10.14 Live Cell Imaging Instruments: Distribution by Multi-user Mode
Figure 10.15 Live Cell Imaging Instruments: Distribution by Z-stack Imaging Capability
Figure 10.16 Live Cell Imaging Instruments: Distribution by Availability of Autofocusing Semi-Autofocusing Ability
Figure 10.17 Live Cell Imaging Instruments: Distribution by Number of Fluorescence Channels
Figure 11.1 Genome Sequencing Technologies: Distribution by Type of Sequencing Technique
Figure 11.2 Genome Sequencing Technologies: Distribution by Maximum Output
Figure 11.3 Genome Sequencing Technologies: Distribution by Maximum Reads per Run
Figure 11.4 Genome Sequencing Technologies: Distribution by Method of Sequencing
Figure 11.5 Genome Sequencing Technologies: Distribution by Year of Establishment
Figure 11.6 Genome Sequencing Technology Providers: Company Size
Figure 11.7 Genome Sequencing Technology Providers: Location of Headquarters
Figure 12.1 Global Spatial Omics Solutions Market, 2022-2035 (USD Billion)
Figure 12.2 Spatial Omics Solutions Market: Distribution by Type of Solution, 2022 and 2035 (USD Billion)
Figure 12.3 Spatial Omics Solutions Market for Instruments, 2022-2035 (USD Billion)
Figure 12.4 Spatial Omics Solutions Market for Services, 2022-2035 (USD Billion)
Figure 12.5 Spatial Omics Solutions Market for Consumables and Software, 2022-2035 (USD Billion)
Figure 12.6 Spatial Omics Solutions Market: Distribution by Type of Sample, 2022 and 2035 (USD Billion)
Figure 12.7 Spatial Omics Solutions Market for Proteins, 2022-2035 (USD Billion)
Figure 12.8 Spatial Omics Solutions Market for RNA, 2022-2035 (USD Billion)
Figure 12.9 Spatial Omics Solutions Market for DNA, 2022-2035 (USD Billion)
Figure 12.10 Spatial Omics Solutions Market: Distribution Research Area, 2022 and 2035 (USD Billion)
Figure 12.11 Spatial Omics Solutions Market for Oncological and Immuno-Oncological Disorders, 2022-2035 (USD Billion)
Figure 12.12 Spatial Omics Solutions Market for Immunological Disorders, 2022-2035 (USD Billion)
Figure 12.13 Spatial Omics Solutions Market for Neurological Disorders, 2022-2035 (USD Billion)
Figure 12.14 Spatial Omics Solutions Market for Infectious Diseases, 2022-2035 (USD Billion)
Figure 12.15 Spatial Omics Solutions Market for Other Research Areas, 2022-2035 (USD Billion)
Figure 12.16 Spatial Omics Solutions Market: Distribution by End User, 2022 and 2035 (USD Billion)
Figure 12.17 Spatial Omics Solutions Market for Pharmaceutical and Biotechnology Companies, 2022-2035 (USD Billion)
Figure 12.18 Spatial Omics Solutions Market for Academic and Research Institutes, 2022-2035 (USD Billion)
Figure 12.19 Spatial Omics Solutions Market: Distribution by Key Geographical Regions, 2022 and 2035 (USD Billion)
Figure 12.20 Spatial Omics Solutions Market in North America, 2022-2035 (USD Billion)
Figure 12.21 Spatial Omics Solutions Market in Europe, 2022-2035 (USD Billion)
Figure 12.22 Spatial Omics Solutions Market in Asia-Pacific and Rest of the World, 2022-2035 (USD Billion)
Figure 12.23 Spatial Omics Solutions Market for Instruments, 2022-2035 (USD Billion)
Figure 12.24 Spatial Omics Solutions Market for Instruments: Distribution by Type of Sample, 2022-2035 (USD Billion)
Figure 12.25 Spatial Omics Solutions Market for Instruments: Distribution by Research Area, 2022-2035 (USD Billion)
Figure 12.26 Spatial Omics Solutions Market for Instruments: Distribution by End User, 2022-2035 (USD Billion)
Figure 12.27 Spatial Omics Solutions Market for Instruments: Distribution by Key Geographical Regions (USD Billion)
Figure 12.28 Spatial Omics Solutions Market for Services, 2022-2035 (USD Billion)
Figure 12.29 Spatial Omics Solutions Market for Services: Distribution by Type of Sample, 2022-2035 (USD Billion)
Figure 12.30 Spatial Omics Solutions Market for Services: Distribution by Research Area, 2022-2035 (USD Billion)
Figure 12.31 Spatial Omics Solutions Market for Services: Distribution by End User, 2022-2035 (USD Billion)
Figure 12.32 Spatial Omics Solutions Market for Services: Distribution by Key Geographical Regions, 2022-2035 (USD Billion)
Figure 12.33 Spatial Omics Solutions Market for Consumables and Software, 2022-2035 (USD Billion)
Figure 12.34 Spatial Omics Solutions Market for Consumables and Software: Distribution by Type of Sample, 2022-2035 (USD Billion)
Figure 12.35 Spatial Omics Solutions Market for Consumables and Software: Distribution by Research Area, 2022-2035 (USD Billion)
Figure 12.36 Spatial Omics Solutions Market for Consumables and Software: Distribution by End User, 2022-2035 (USD Billion)
Figure 12.37 Spatial Omics Solutions Market for Consumables and Software: Distribution by Key Geographical Regions, 2022-2035 (USD Billion)
Figure 14.1 Concluding Remarks: Overall Market Landscape of Spatial Omics Solutions
Figure 14.2 Concluding Remarks: Partnerships and Collaborations
Figure 14.3 Concluding Remarks: Patent Analysis
Figure 14.4 Concluding Remarks: Publication Analysis
Figure 14.5 Concluding Remarks: Live Cell Imaging Instruments
Figure 14.6 Concluding Remarks: Market Sizing and Opportunity Analysis - I
Figure 14.7 Concluding Remarks: Market Sizing and Opportunity Analysis- II
Table 3.1 Contrasting Characteristics: Fluorescence Microscopy and Brightfield Microscopy
Table 3.2 Spatial Omics Analysis Algorithms
Table 4.1 Spatial Omics Solutions: Information on Developer, Commercial Availability, Type of Solution(s) Offered, Type of Sample(s) Analyzed and Supported Labware
Table 4.2 Spatial Omics Solutions: Information on Type of Molecule(s) Analyzed, Detection Method (s) Used, Maximum Plex Level and Quantification Capability
Table 4.3 Spatial Omics Solutions: Information on Research Area(s), Technology / Software Used, Application Area(s) and Compatible Sample Source(s)
Table 4.4 Spatial Omics Solution Providers: List of Industry and Non-Industry Players
Table 4.5 Spatial Omics Solutions: List of Kits
Table 4.6 Spatial Omics Solutions: Funding and Investment, Information on Type of Funding, Year of Investment, Amount Invested and Name of the Investor(s), 2017 - Q2 2022
Table 6.1 Spatial Omics Solutions: List of Companies Profiled
Table 6.2 10x Genomics: Company Snapshot
Table 6.3 10x Genomics: Product Portfolio
Table 6.4 10x Genomics: Recent Developments and Future Outlook
Table 6.5 Akoya Biosciences: Company Snapshot
Table 6.6 Akoya Biosciences: Product Portfolio
Table 6.7 Akoya Biosciences: Recent Developments and Future Outlook
Table 6.8 Bruker: Company Snapshot
Table 6.9 Bruker: Product Portfolio
Table 6.10 Bruker: Recent Developments and Future Outlook
Table 6.11 Canopy Biosciences: Company Snapshot
Table 6.12 Canopy Biosciences: Product Portfolio
Table 6.13 Canopy Biosciences: Recent Developments and Future Outlook
Table 6.14 NanoString Technologies: Company Snapshot
Table 6.15 NanoString Technologies: Product Portfolio
Table 6.16 NanoString Technologies: Recent Developments and Future Outlook
Table 6.17 Vizgen: Company Snapshot
Table 6.18 Vizgen: Product Portfolio
Table 6.19 Vizgen: Recent Developments and Future Outlook
Table 6.20 Lunaphore Technologies: Company Snapshot
Table 6.21 Lunaphore Technologies: Product Portfolio
Table 6.22 Lunaphore Technologies: Recent Developments and Future Outlook
Table 6.23 Molecular Machines & Industries (MMI): Company Snapshot
Table 6.24 Molecular Machines & Industries (MMI): Product Portfolio
Table 6.25 Molecular Machines & Industries (MMI): Recent Developments and Future Outlook
Table 6.26 Resolve Biosciences: Company Snapshot
Table 6.27 Resolve Biosciences: Product Portfolio
Table 6.28 Resolve Biosciences: Recent Developments and Future Outlook
Table 7.1 Spatial Omics Solutions: List of Partnerships and Collaborations, 2016-2022 (till April)
Table 8.1 Patent Analysis: Most Prominent CPC Symbols Definitions
Table 8.2 Patent Analysis: Most Popular CPC Symbols
Table 8.3 Patent Analysis: List of Top CPC Symbols
Table 8.4 Patent Analysis: Summary of Benchmarking Analysis
Table 8.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 8.6 Patent Portfolio: List of Leading Patents (in terms of Highest Relative Valuation)
Table 8.7 Patent Portfolio: List of Leading Patents (in terms of Number of Citations)
Table 10.1 Live Cell Imaging Instruments Providers: List of Industry Players
Table 10.2 Live Cell Imaging Instruments: Information on Commercial Availability, Integrated Technology / Software and Product Dimensions
Table 10.3 Live Cell Imaging Instruments: Information on Microscope configuration, Operating Conditions, Environmental Parameters Controlled and Supported Labware
Table 10.4 Live Cell Imaging Instruments: Information on Mode of Imaging, Multi-User Mode, Z-stack Imaging, Autofocusing / Semi-Autofocusing Capability, Number of Fluorescent Channels and Magnification
Table 11.1 Genome Sequencing: List of Available Technologies
Table 11.2 Genome Sequencing Technologies: Additional Details
Table 11.3 Genome Sequencing: List of Technology Providers
Table 15.1 Spatial Omics Solutions: Distribution by Commercial Availability
Table 15.2 Spatial Omics Solutions: Distribution by Type of Solution Offered
Table 15.3 Spatial Omics Solutions: Distribution by Type of Sample Analyzed
Table 15.4 Spatial Omics Solutions: Distribution by Compatible Sample Source
Table 15.5 Spatial Omics Solutions: Distribution by Supporting Labware
Table 15.6 Spatial Omics Solutions: Distribution by Type of Molecule Analyzed
Table 15.7 Spatial Omics Solutions: Distribution by Detection Method Used
Table 15.8 Spatial Omics Solutions: Distribution by Maximum Plex Level
Table 15.9 Spatial Omics Solutions: Distribution by Quantification Capability
Table 15.10 Spatial Omics Solutions: Distribution by Research Area
Table 15.11 Spatial Omics Solutions: Distribution by Application Area
Table 15.12 Spatial Omics Solutions: Distribution by Compatible Sample Source and Type of Sample Analyzed
Table 15.13 Spatial Omics Solutions: Distribution by Quantification Capability and Type of Molecule Analyzed
Table 15.14 Spatial Omics Solutions: Distribution by Quantification Capability and Type of Molecule Analyzed
Table 15.15 Spatial Omics Solutions Providers: Distribution by Type of Player
Table 15.16 Spatial Omics Solutions Providers: Distribution by Year of Establishment
Table 15.17 Spatial Omics Solutions Providers: Distribution by Company Size
Table 15.18 Spatial Omics Solutions Providers: Distribution by Location of Headquarters
Table 15.19 Spatial Omics Solutions Providers: Distribution by Company Ownership
Table 15.20 Spatial Omics Solutions Providers: Distribution by Year of Establishment and Location of Headquarters
Table 15.21 Spatial Omics Solutions Providers: Distribution by Distribution by Company Size and Location of Headquarters
Table 15.22 10x Genomics: Annual Revenues, FY 2017-Q2 FY 2022 (USD Billion)
Table 15.23 Akoya Biosciences: Annual Revenues, FY 2019- Q2 FY 2022 (USD Million)
Table 15.24 Bruker: Annual Revenues, FY 2017- Q2 FY 2022 (USD Million)
Table 15.25 NanoString Technologies: Annual Revenues, FY 2017- Q2 FY 2022 (USD Billion)
Table 15.26 Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2022
Table 15.27 Partnerships and Collaborations: Distribution by Type of Partnership
Table 15.28 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 15.29 Partnerships and Collaborations: Distribution by Distribution by Type of Partner
Table 15.30 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 15.31 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 15.32 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 15.33 Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
Table 15.34 Partnerships and Collaborations: Distribution by Regional Distribution
Table 15.35 Most Active Players: Distribution by Number of Partnerships
Table 15.36 Patent Analysis: Distribution by Type of Patent
Table 15.37 Patent Analysis: Distribution by Patent Application Year, 2003-2022 (till February)
Table 15.38 Patent Analysis: Distribution by Patent Publication Year, 2003-2022 (till February)
Table 15.39 Patent Analysis: Distribution by Granted Patents, 2003-2022 (till February)
Table 15.40 Patent Analysis: Distribution by Patent Application Ye Patent Analysis: Year-wise Trend of Filed Patent Applications, 2003-2022 (till February)
Table 15.41 Patent Analysis: Distribution by Granted Patents and Patent Applications, 2003- 2022 (till February)
Table 15.42 Patent Analysis: Distribution by Geography
Table 15.43 Patent Analysis: Distribution by Patent Age
Table 15.44 Patent Analysis: Distribution by Type of Applicant
Table 15.45 Patent Analysis: Distribution by CPC Symbols
Table 15.46 Leading Academic Players: Distribution by Number of Patents
Table 15.47 Leading Non-Academic Players: Distribution by Number of Patents
Table 15.48 Top Inventors: Distribution by Number of Patents
Table 15.49 Patent Analysis: Patent Benchmarking Analysis
Table 15.50 Patent Analysis: Distribution by Patent Valuation Analysis
Table 15.51 Publication Analysis: Distribution by Year and Quarter of Publication, 2001-2022 (till February)
Table 15.52 Publication Analysis: Distribution by Month and Quarter of Publication, 2001-2022
Table 15.53 Publication Analysis: Distribution by Year of Publication, 2001-2022 (till February)
Table 15.54 Publication Analysis: Distribution by Type of Publication
Table 15.55 Popular Journals: Distribution by Number of Publications
Table 15.56 Key Journals: Distribution by Impact Factor
Table 15.57 Popular Publishers: Distribution by Number of Publications
Table 15.58 Popular Copyright Holders: Distribution by Number of Publications
Table 15.59 Live Cell Imaging Instruments Providers: Distribution by Year of Establishment
Table 15.60 Live Cell Imaging Instruments Providers: Distribution by Company Size
Table 15.61 Live Cell Imaging Instruments Providers: Distribution by Location of Headquarters
Table 15.62 Live Cell Imaging Instruments Providers: Distribution by Company Ownership
Table 15.63 Live Cell Imaging Instruments Providers: Distribution by Year of Establishment and Location of Headquarters
Table 15.64 Live Cell Imaging Instruments Providers: Distribution by Company Size and Location of Headquarters
Table 15.65 Live Cell Imaging Instruments: Distribution by Commercial Availability
Table 15.66 Live Cell Imaging Instruments: Distribution by Microscope Weight
Table 15.67 Live Cell Imaging Instruments: Distribution by Microscope Configuration
Table 15.68 Live Cell Imaging Instruments: Distribution by Incubator Integrated and Environmental Parameters Controlled
Table 15.69 Live Cell Imaging Instruments: Distribution by Availability of Multi-user Mode
Table 15.70 Live Cell Imaging Instruments: Distribution by Supported Labware
Table 15.71 Live Cell Imaging Instruments: Distribution by Z-stack Imaging Capability
Table 15.72 Live Cell Imaging Instruments: Distribution by Autofocusing / Semi-Autofocusing Capability
Table 15.73 Live Cell Imaging Instruments: Distribution by Mode of Imaging
Table 15.74 Live Cell Imaging Instruments: Distribution by Number of Fluorescence Channels
Table 15.75 Live Cell Imaging Instruments: Distribution by Magnification
Table 15.76 Live Cell Imaging Instruments: Distribution by Mode of Imaging, Availability of multi-user Mode, Z-stack Imaging Capability, and Autofocusing / Semi- autofocusing Capability
Table 15.77 Genome Sequencing Technologies Providers: Distribution by Year of Establishment
Table 15.78 Genome Sequencing Technologies Providers: Distribution by Company Size
Table 15.79 Genome Sequencing Technologies Providers: Distribution by Location of Headquarters
Table 15.80 Genome Sequencing Technologies: Distribution by Type of Application
Table 15.81 Genome Sequencing Technologies: Distribution by Maximum Output
Table 15.82 Genome Sequencing Technologies: Distribution by Maximum Reads per Run
Table 15.83 Genome Sequencing Technologies: Distribution by Sequencing Technique
Table 15.84 Spatial Omics Solutions Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 15.85 Spatial Omics Solutions Market: Distribution by Type of Solution, 2022 and 2035 (USD Billion)
Table 15.86 Spatial Omics Solutions Market for Instruments, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 15.87 Spatial Omics Solutions Market for Services, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 15.88 Spatial Omics Solutions Market for Consumables and Software, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 15.89 Spatial Omics Solutions Market: Distribution by Type of Sample, 2022 and 2035 (USD Billion)
Table 15.90 Spatial Omics Solutions Market for Proteins, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 15.91 Spatial Omics Solutions Market for RNA, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 15.92 Spatial Omics Solutions Market for DNA, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 15.93 Spatial Omics Solutions Market: Distribution by Research Area, 2022 and 2035 (USD Billion)
Table 15.94 Spatial Omics Solutions Market for Oncological and Immuno-oncological Disorders, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 15.95 Spatial Omics Solutions Market for Immunological Disorders, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 15.96 Spatial Omics Solutions Market for Neurological Disorders, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 15.97 Spatial Omics Solutions Market for Infectious Diseases, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 15.98 Spatial Omics Solutions Market for Other Research Areas, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 15.99 Spatial Omics Solutions Market: Distribution by End User, 2022 and 2035 (USD Billion)
Table 15.100 Spatial Omics Solutions Market for Pharmaceutical and Biotechnology Companies, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 15.101 Spatial Omics Solutions Market for Academic and Research Institutes, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 15.102 Spatial Omics Solutions Market: Distribution by Key Geographical Regions, 2022 and 2035 (USD Billion)
Table 15.103 Spatial Omics Solutions Market for North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 15.104 Spatial Omics Solutions Market for Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 15.105 Spatial Omics Solutions Market for APAC / RoW, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 15.106 Spatial Omics Solutions Market for Instruments, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 15.107 Spatial Omics Solutions Market for Instruments: Distribution by Type of Sample, 2022-2035 (USD Billion)
Table 15.108 Spatial Omics Solutions Market for Instruments, Distribution by Research Area, 2022-2035 (USD Billion)
Table 15.109 Spatial Omics Solutions Market for Instruments: Distribution by End User, 2022-2035 (USD Billion)
Table 15.110 Spatial Omics Solutions Market for Instruments: Distribution by Key Geographical Regions, 2022-2035 (USD Billion)
Table 15.111 Spatial Omics Solutions Market for Services, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 15.112 Spatial Omics Solutions Market for Services: Distribution by Type of Sample, 2022-2035 (USD Billion)
Table 15.113 Spatial Omics Solutions Market for Services: Distribution by Research Area, 2022-2035 (USD Billion)
Table 15.114 Spatial Omics Solutions Market for Services: Distribution by End User, 2022-2035 (USD Billion)
Table 15.115 Spatial Omics Solutions Market for Services: Distribution by Region, 2022-2035 (USD Billion)
Table 15.116 Spatial Omics Solutions Market for Consumables and Software, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 15.117 Spatial Omics Solutions Market for Consumables and Software: Distribution by Type of Sample, 2022-2035 (USD Billion)
Table 15.118 Spatial Omics Solutions Market for Consumables and Software: Distribution by Research Area, 2022-2035 (USD Billion)
Table 15.119 Spatial Omics Solutions Market for Consumables and Software: Distribution by End User, 2022-2035 (USD Billion)
Table 15.120 Spatial Omics Solutions Market for Consumables and Software: Distribution by Region, 2022-2035 (USD Billion)
The following companies and organizations have been mentioned in the report:
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
YOU MAY ALSO LIKE
SUBSCRIBE TO INDUSTRY UPDATES